Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525221-21-01

Enrollment

180

Registered

2026-07-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Brief summary

24 months

Detailed description

Year 5

Interventions

DRUGJyseleca 200 mg film-coated tablets

DRUGOlumiant 4 mg film-coated tablets

DRUGINFLIXIMAB

DRUGCERTOLIZUMAB PEGOL

DRUGHYDROXYCHLOROQUINE

DRUGRINVOQ 15 mg prolonged-release tablets

DRUGADALIMUMAB

DRUGSULFASALAZINE

DRUGSARILUMAB

DRUGRoActemra 162 mg solution for injection in pre-filled syringe.

DRUGMETHOTREXATE

DRUGGOLIMUMAB

DRUGORENCIA 250 mg powder for concentrate for solution for infusion

DRUGPrednisolone 5mg Soluble Tablets

DRUGXELJANZ 5 mg film-coated tablets

DRUGLEFLUNOMIDE

DRUGETANERCEPT

DRUGRoActemra 20 mg/mL concentrate for solution for infusion

DRUGORENCIA 125 mg solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
24 months	—

Secondary

Measure	Time frame
Year 5	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 7, 2026